KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Equity Average (2018 - 2025)

Amneal Pharmaceuticals (AMRX) has 8 years of Equity Average data on record, last reported at -$90.6 million in Q4 2025.

  • For Q4 2025, Equity Average rose 10.73% year-over-year to -$90.6 million; the TTM value through Dec 2025 reached -$90.6 million, up 10.73%, while the annual FY2025 figure was -$90.4 million, 102.05% down from the prior year.
  • Equity Average reached -$90.6 million in Q4 2025 per AMRX's latest filing, up from -$111.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $387.2 million in Q1 2022 and bottomed at -$122.3 million in Q2 2025.
  • Average Equity Average over 5 years is $119.2 million, with a median of $147.6 million recorded in 2023.
  • The widest YoY moves for Equity Average: up 10.73% in 2025, down 453.7% in 2025.
  • A 5-year view of Equity Average shows it stood at $375.1 million in 2021, then tumbled by 49.57% to $189.1 million in 2022, then crashed by 53.94% to $87.1 million in 2023, then crashed by 216.55% to -$101.5 million in 2024, then grew by 10.73% to -$90.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were -$90.6 million in Q4 2025, -$111.2 million in Q3 2025, and -$122.3 million in Q2 2025.